Article info

Download PDFPDF
Anlotinib in recurrent or metastatic endometrial cancer

Authors

  • Qingli Cui Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  • Yuefeng Mao Department of Medical Oncology, Second People's Hospital of Pingdingshan, Pingdingshan, Henan, China PubMed articlesGoogle scholar articles
  • Yanhui Hu Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  • Dongyang Ma Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  • Huaimin Liu Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Huaimin Liu, Department of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450003, China; huaiminliu{at}sina.com
View Full Text

Citation

Cui Q, Mao Y, Hu Y, et al
Anlotinib in recurrent or metastatic endometrial cancer

Publication history

  • Received January 2, 2022
  • Accepted April 26, 2022
  • First published May 23, 2022.
Online issue publication 
September 06, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.